Results 31 to 40 of about 5,561 (172)

4-[3,5-Bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl]benzoic acid dimethylformamide monosolvate

Acta Crystallographica Section E, 2012
In the molecule of deferasirox dimethylformamide solvate, C21H15N3O4·C3H7NO, the central 1,2,4-triazole ring is tilted with respect to the benzoic acid and one of the 2-hydroxyphenyl units but coplanar with the other 2-hydroxyphenyl group, as ...
H. S. Yathirajan, Saji Thomas, A. S. Dayananda, Suchada Chantrapromma, Hoong-Kun Fun   +4 more
doaj   +1 more source

Inconsistent hepatic antifibrotic effects with the iron chelator deferasirox

, 2015
Background and AimDevelopment of effective antifibrotic treatments that can be translated to clinical practice is an important challenge in contemporary hepatology. A recent report on -thalassemia patients demonstrated that deferasirox treatment reversed
Bridle, Kim R., de Guzman, C. Erika, Jaskowski, Lesley, Subramaniam, V. Nathan, Jaskowski, L., Campbell, Catherine M., Crawford, D.H.G., Crawford, Darrell H. G., de Guzman, C.E., Santrampurwala, N., Campbell, C.M., Sobbe, Amy, Santrampurwala, Nishreen, Sobbe, A., Bridle, K.R., Clouston, Andrew D., Clouston, A.D., Subramaniam, V.N.   +17 more
core   +1 more source

Deferasirox is a powerful NF-κB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging

Haematologica, 2010
Background Usefulness of iron chelation therapy in myelodysplastic patients is still under debate but many authors suggest its possible role in improving survival of low-risk myelodysplastic patients.
Emanuela Messa, Sonia Carturan, Chiara Maffè, Marisa Pautasso, Enrico Bracco, Antonella Roetto, Francesca Messa, Francesca Arruga, Ilaria Defilippi, Valentina Rosso, Chiara Zanone, Antonia Rotolo, Elisabetta Greco, Rosa M. Pellegrino, Daniele Alberti, Giuseppe Saglio, Daniela Cilloni   +16 more
doaj   +1 more source

The potential of deferasirox as a novel therapeutic modality in gastric cancer [PDF]

, 2016
Background: Iron is a crucial element for cell proliferation, growth, and metabolism. However, excess iron and altered iron metabolism are both associated with tumor initiation and tumor growth. Deferasirox is an oral iron chelator. Although some studies
���������
core   +1 more source

Comparison of deferasirox and deferoxamine effects on iron overload and immunological changes in patients with blood transfusion-dependent β-thalassemia

Asian Journal of Transfusion Science, 2017
Introduction: Beta-thalassemias are a cluster of inherited (autosomal recessive) hematological disorders prevalent in the Mediterranean area due to defects in synthesis of β chains of hemoglobin.
Hayder M Al-Kuraishy, Ali I Al-Gareeb
doaj   +1 more source

The Clinically Used Iron Chelator Deferasirox Is an Inhibitor of Epigenetic JumonjiC Domain-Containing Histone Demethylases

, 2019
\ua9 2019 American Chemical Society.Fe(II)- and 2-oxoglutarate (2OG)-dependent JumonjiC domain-containing histone demethylases (JmjC KDMs) are "epigenetic eraser" enzymes involved in the regulation of gene expression and are emerging drug targets in ...
Abboud MI, Tzu-lan, Yeh, Yeh T-L, Martin, Roatsch, Akane, Kawamura, Wenzler S, Dina, Robaa, Wilkins SE, Manfred, Jung, Roatsch M, Martine I., Abboud, Isabelle, Moneke, Ahrens TD, Schule R, Wolfgang, Sippl, Rebecca L., Hancock, Robaa D, Schleicher E, Kerstin, Lippl, Erik, Schleicher, Sippl W, Hancock RL, Serrer K, Sarah E., Wilkins, Lassmann S, Barthes NPF, Kerstin, Serrer, Diederichs S, Kuo-Feng, Hsu, Sandra, Wenzler, Silke, Lassmann, Tarhonskaya H, Theresa D., Ahrens, Hanna, Tarhonskaya, Franz H, Inga, Hoffmann, Schofield CJ, Hsu K-F, Sven, Diederichs, Henriette, Franz, Hoffmann I, Moneke I, Kawamura A, Roland, Schüle, Jung M, Christopher J., Schofield, Lippl K   +46 more
core   +1 more source

Újonnan kifejlesztett termék gyártástechnológiájának üzemi szintű adaptálása

, 2023
Szakdolgozatomban a deferasirox hatóanyagtartalmú gyógyszer fejlesztésből gyártásba történő transzferét mutatom be, melynek során vizsgálom a gyártási paramétereit:mely paraméter változtatása befolyásolja a termék minőségét.
Juhász, Csilla
core  

Deferasirox: pharmacokinetics and clinical experience

, 2012
Introduction: Iron overload is an inevitable consequence of transfusion therapy for a variety of underlying anemias. Iron overload, without effective chelation, will lead to significant morbidity and mortality. Deferasirox (Exjade®) is an oral tridentate
ORIGA, RAFFAELLA, GALANELLO, RENZO, Campus S   +2 more
core   +1 more source

Chelation of aluminum by combining deferasirox and deferiprone in rats

, 2011
The hypothesis that two known chelators deferasirox and deferiprone (L1) might be more efficient as combined treatment than as single therapies in removing aluminum from the body was tested in a new acute rat model.
Amir Shokooh Saljooghi
core   +1 more source

Single-center retrospective study of the effectiveness and toxicity of the oral iron chelating drugs deferiprone and deferasirox.

PLoS ONE, 2019
BACKGROUND:Iron overload, resulting from blood transfusions in patients with chronic anemias, has historically been controlled with regular deferoxamine, but its parenteral requirement encouraged studies of orally-active agents, including deferasirox and
Nancy F Olivieri, Amir Sabouhanian, Brenda L Gallie   +2 more
doaj   +1 more source